SLGL

Sol-GelD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

Current thesis

The main bull case is that March 2026 financing plus prior Mayne proceeds give SLGL enough runway to reach the SGT-610 Phase 3 readout without an immediate balance-sheet crisis, leaving the stock levered to a rare-disease dermatology asset with meaningful orphan optionality [#20F-2026-03-19] [#6K-2026-03-24].

Posture

Defensive

Lead driver

Value

What changed

Value remains the lead driver in the composite, 7D delta -0.1.

What can break

Commercial and partnering assumptions outside the U.S. remain hard to verify in real time.

Momentum

Value

Sentiment

Setup hits (3d)

— · Net —

AI TargetsBase $72.00 · Bull $100.00 · Bear $40.00

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2026-04-17 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade D · Defensive

Confidence Medium · Net —

Target $234.50

Why

Momentum68 · Δ7d -14.7

Value48 · Δ7d -0.1

Sentiment30 · Δ7d +0.1

So what

Weak posture. Prioritize risk control and patience.

Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits

Lead driver: Value · See fundamentals

Momentum

26% active weight

Current posture

7d trendSoftening

Δ7d

-14.7

Δ21d

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.1

Δ21d

+0.0

Sentiment

34% active weight

Current posture

7d trendFlat

Δ7d

+0.1

Δ21d

Why this grade

Composite grade D. Momentum 68.0 / Value 48.3 / Sentiment 29.8

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$271.98M

Beta

1.36

Shares Out

3.27M

P/E (TTM) · Derived

-37.8

P/S (TTM)

6.49

P/FCF (TTM) · Derived

-19.58

Rev YoY

-89.5%

EPS YoY

-58.5%

Gross Margin

+100.0%

Op Margin

-53.9%

Net Debt

-$23.01M

Current Ratio

8.84

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology